WallStreetZenWallStreetZen

NASDAQ: CTNM
Contineum Therapeutics Inc Stock Ownership - Who owns Contineum Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Contineum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Tim WatkinsCMO Head of Development2026-03-023,611$15.02
$54.22kSell
Daniel S. LorrainChief Scientific Officer2026-03-024,170$15.01
$62.58kSell
Tim WatkinsCMO Head of Development2026-03-023,611$4.50
$16.25kBuy
Daniel S. LorrainChief Scientific Officer2026-02-253,824$1.01
$3.86kBuy
Carmine N. StengoneCEO and President2026-02-252,700$1.26
$3.40kBuy
Carmine N. StengoneCEO and President2026-02-252,700$16.02
$43.24kSell
Daniel S. LorrainChief Scientific Officer2026-02-253,824$16.01
$61.23kSell
Carmine N. StengoneCEO and President2026-02-244,400$1.26
$5.54kBuy
Daniel S. LorrainChief Scientific Officer2026-02-244,300$1.01
$4.34kBuy
Daniel S. LorrainChief Scientific Officer2026-02-244,300$16.03
$68.94kSell

1 of 3

CTNM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CTNM insiders and whales buy or sell their stock.

CTNM Shareholders

What type of owners hold Contineum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Suvretta Capital Management LLC7.61%2,841,334$36.94MInstitution
Janus Henderson Group PLC6.56%2,448,979$31.84MInstitution
Ra Capital Management LP5.84%2,179,711$28.34MInstitution
Johnson Johnson5.30%1,979,173$25.73MInstitution
Johnson Johnson5.30%1,979,173$25.73MInsider
Franklin Resources Inc5.03%1,879,367$24.43MInstitution
Balyasny Asset Management LP4.94%1,842,800$23.96MInstitution
Perceptive Advisors LLC3.92%1,464,592$19.04MInstitution
Baker Bros Advisors LP3.81%1,420,838$18.47MInstitution
Vanguard Group Inc3.40%1,270,858$16.52MInstitution

1 of 3

CTNM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CTNM79.21%7.20%Net SellingNet Selling
FULC70.01%29.99%Net SellingNet Selling
PRTA52.47%47.53%Net Selling
RIGL39.34%60.66%Net SellingNet Selling
VSTM60.59%39.41%Net SellingNet Selling
View Top Biotech Stocks

Contineum Therapeutics Stock Ownership FAQ

Who owns Contineum Therapeutics?

Contineum Therapeutics (NASDAQ: CTNM) is owned by 79.21% institutional shareholders, 7.20% Contineum Therapeutics insiders, and 13.58% retail investors. Johnson Johnson is the largest individual Contineum Therapeutics shareholder, owning 1.98M shares representing 5.30% of the company. Johnson Johnson's Contineum Therapeutics shares are currently valued at $26.46M.

If you're new to stock investing, here's how to buy Contineum Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.